UroGen Pharma Ltd.
UGN-103
recurrent LG-IR-NMIBC
Resolved
131days ago
Phase 3 readout · Feb 26, 2026
What's at stake
Phase 3 trial results for UGN-103 in recurrent LG-IR-NMIBC are due Feb 26, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“UGN-103 demonstrated a 77.8% three-month complete response (CR) rate (95% CI, 68.3%, 85.5%).”